PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Surgery, University Medical Center Groningen (UMCG), Hanzeplein 1, 9700 RB Groningen, the Netherlands.\', \'Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), Hanzeplein 1, 9700 RB Groningen, the Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), Hanzeplein 1, 9700 RB Groningen, the Netherlands.\', \'Akston Biosciences Corporation, 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States.\', \'Feigin ABSL-3 Facility, Department of Pediatrics-Division of Tropical Medicine, Baylor College of Medicine and Texas Children\'s Hospital, 1102 Bates Ave, 300.15, Houston, TX 77030, United States.\', \'TRACER BV, L.J. Zielstraweg 1, 9766 GX Groningen, the Netherlands.\', \'ICON, van Swietenlaan 6, 9728 NZ Groningen, the Netherlands.\', \'Department of Surgery, University Medical Center Groningen (UMCG), Hanzeplein 1, 9700 RB Groningen, the Netherlands; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), Hanzeplein 1, 9700 RB Groningen, the Netherlands.\', \'Akston Biosciences Corporation, 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States. Electronic address: todd.zion@akstonbio.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(22)00077-910.1016/j.vaccine.2022.01.043
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 35115195
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all